This report was first published by Endpoints News. To see the original version, click here
Eli Lilly keeps putting its GLP-1 windfall to use.
On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as $2.3 billion on Ajax Therapeutics and its clinical-stage JAK2 work in blood cancer. Lilly and Ajax didn’t disclose how much of that is in cash, and how much is in future results-based incentive payouts.
您已阅读12%（479字），剩余88%（3610字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。